Vernalis at buy by Merrill

Vernalis plc was rated at a buy by Merrill Lynch analyst Robin Campbell on news that the company missed on Apokyn guidance in the first half of 2006. Pipeline events over the next six to 12 months and a potential Frova approval are key to keeping the share price on the up, according to the analyst. Shares of the Cambridge, England-based pharmaceutical company were unchanged at 66p. (London: VER)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.